Christine Allen
This sandbox is in the article namespace. Either move this page into your userspace, or remove the {{User sandbox}} template. Christine Allen is a Canadian Professor and GlaxoSmithKline Chair in Pharmaceutics and Drug Delivery, University of Toronto in the Leslie Dan Faculty of Pharmacy. She is the co-Founder of Nanovista[1], which is a company focused on imaging of tumors. [1] Currently, she serves as Associate Editor of Molecular Pharmaceutics.[2] She received her PhD in Chemistry at McGill University and completed a post doc in the Department of Advanced Therapeutics at the BC Cancer Agency. Prior to joining University of Toronto in 2002 she worked as a scientist and assistant directors of materials research at Celator Pharmaceuticals.[2] Dr. Allen's research is focused in the field of drug delivery. In particular, micelles and gold nanoparticles for cancer therapy.[3][4] She has developed several block-co-polymers, particularly those with PEG, for delivery of cancer chemotherapeutics.[3] For cancer imaging as well as theranostic applications, the Allen lab has developed several gold nanoparticle carriers.[4] Her platforms apply concepts in drug delivery, targeted drug delivery, as well as controlled release. She has numerous patents, and over 90 publications.[2] Also, she has received many awards including:
- 2014 Gattefossé Canada/CSPS Award in Lipid-Based Drug Delivery[5]
- 2011 CRS/Elsevier Journal of Controlled Release Jorge Heller Award for Outstanding Paper[6]
- Innovation Award - Ontario Research and Commercialization Program, 2008
- Career Award - Canadian Institutes of Health Research (CIHR)/Rx&D, 2004-2009
- New Investigator Research Award - Association of Faculties of Pharmacy of Canada (AFPC)/AstraZeneca, 2006
- Early Career Award - Canadian Society for Pharmaceuticals Sciences (CSPS)/GlaxoSmithKline, 2006
References
- ^ "Christine Allen Women enabling science to reach the people who need it". Johnson & Johnson Innovation Labs. Retrieved 30 July 2018.
- ^ a b c "Christine Allen". Controlled Release Society. Retrieved 30 July 2018.
- ^ a b Houdaihed, L; Evans, JC; Allen, C (2017). "Overcoming the Road Blocks: Advancement of Block Copolymer Micelles for Cancer Therapy in the Clinic". Mol Pharm. 14 (8): 2503-2517. PMID 28481116. Retrieved 1 August 2018.
- ^ a b Her, S; Jaffray, DA; Allen, C (2017). "Gold nanoparticles for applications in cancer radiotherapy: Mechanisms and recent advancements". Adv Drug Deliv Rev. 109: 84-101. PMID 26712711. Retrieved 1 August 2018.
- ^ Dou, Yannan; Zheng, Jinzi; Foltz, Warren; Weersink, Robert; Chaudary, Naz; Jaffray, David; Allen, Christine (25 September 2011). "Heat-activated thermosensitive liposomal cisplatin (HTLC) results in effective growth delay of cervical carcinoma in mice". Journal of Controlled Release. 178 (23): 69-78. PMID 24440663. Retrieved 31 July 2018.
- ^ Dunn, Michael; Zheng, Jinzi; Rosenblat, Joshua; Jaffray, David; Allen, Christine (25 September 2011). "APN/CD13-targeting as a strategy to alter the tumor accumulation of liposomes". Journal of Controlled Release. 154 (3): 298-305. PMID 21640146. Retrieved 31 July 2018.
This article, Christine Allen, has recently been created via the Articles for creation process. Please check to see if the reviewer has accidentally left this template after accepting the draft and take appropriate action as necessary.
Reviewer tools: Inform author |